<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04243863</url>
  </required_header>
  <id_info>
    <org_study_id>VNRX-7145-101</org_study_id>
    <secondary_id>272201600029C-P00007-9999-2</secondary_id>
    <secondary_id>18-0012</secondary_id>
    <nct_id>NCT04243863</nct_id>
  </id_info>
  <brief_title>VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-7145 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VenatoRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>VenatoRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part, first-in-human dose-ranging study to evaluate the safety and
      pharmacokinetics of escalating doses of VNRX-7145. In part 1, subjects will receive a single
      dose of VNRX-7145; in part 2 subjects will receive multiple doses of VNRX-7145 for 10 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of subjects with adverse events</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of subjects with adverse events</measure>
    <time_frame>Day 17</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC0-tau</measure>
    <time_frame>Days 1-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmax</measure>
    <time_frame>Days 1-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: tmax</measure>
    <time_frame>Days 1-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: CLr</measure>
    <time_frame>Days 1-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC0-tau</measure>
    <time_frame>Days 1-10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax</measure>
    <time_frame>Days 1-10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: tmax</measure>
    <time_frame>Days 1-10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: CLr</measure>
    <time_frame>Days 1-10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>VNRX-7145</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VNRX-7145</intervention_name>
    <description>Part 1: one dose Part 2: 28 doses (once every 8 hour [q8h] dosing for 9 days with a single morning dose on Day 10)</description>
    <arm_group_label>VNRX-7145</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Part 1: one dose Part 2: 28 doses (once every 8 hour [q8h] dosing for 9 days with a single morning dose on Day 10)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults 18-45 years

          -  Males or non-pregnant, non-lactating females

          -  Body mass index (BMI): ≥18.5 kg/m² and ≤32.0 kg/m²

          -  Normal blood pressure

          -  Normal laboratory tests

        Exclusion Criteria:

          -  Current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine,
             autoimmune, hematologic, neoplastic, or neurological disorder

          -  History of drug allergy

          -  Abnormal ECG or history of clinically significant abnormal rhythm disorder

          -  Positive alcohol, drug, or tobacco use/test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Venatorx Clinical</last_name>
    <phone>610-644-8935</phone>
    <email>venatorxclinical@venatorx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Worldwide Clinical Trials Early Phase Services, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>July 25, 2020</last_update_submitted>
  <last_update_submitted_qc>July 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VNRX-7145</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

